ArticleBioactive materials2025
Suprachoroidal space-inducing hydrogel-forming microneedles (SI-HFMN): An innovative platform for drug delivery to the posterior segment of the eye.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advanced Ophthalmic Drug Delivery in Homocystinuria Type CblC: A Translational Review of Ophthalmic Pathologies and Therapeutic Opportunities.Pharmaceutics · 2026Review
- Exosome-based therapies for corneal disorders: current status and future perspectives.MedScience · 2026Review
- Biosensor-Integrated Microneedle Devices for Diagnosis and Treatment of Chronic and Infectious Diseases: Current Status, Trends and Challenges.Biosensors · 2026Review
- Advanced Corneal Hydrogels: From Passive Replacement to Active Regeneration and Intelligent Interaction.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Advances in microneedle Technology for Treatment of retinal degenerative diseases: a narrative review.Biomedical microdevices · 2026Review
- Celecoxib and shikonin loaded dissolving microneedle exert analgesic, anti-inflammatory and chondroprotective activity for osteoarthritis treatment.Frontiers in cell and developmental biology · 2026Article
- Microneedles in biomedicine: Innovations, challenges, and future prospects.Biomaterials translational · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The suprachoroidal space (SCS), which exists between the sclera and choroid, offers a promising delivery route to the posterior segment of the eye (PSE) and is integrated with hollow microneedles (HMNs) for minimally invasive delivery. However, HMNs are limited by backflow owing to their narrow channel. Therefore, this study proposes a biocompatible SCS-inducing hydrogel-forming microneedle (SI-HFMN) with a specially designed candlelit shape that swells to separate the sclera from the choroid. The induced SCS provides a route for delivering loaded drugs to the PSE upon application. The optimized formulation of 20 % (w/w) poly(methyl vinyl ether-alt-maleic acid) (PMVE/MA) crosslinked with 7.5 % (w/w) polyethylene glycol (PEG) possesses sufficient mechanical strength (5.1 ± 0.7 N) to penetrate both the sclera and swell by 356 ± 28 %, to mechanically stimulate SCS formation. The formulation also recorded a drug absorption amount of 101 ± 9 μg/mg of hydrogel. Furthermore,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.